Earnings Call · Q2 FY2023·2023-08-10

Q2 23EPS +22.22%·Rev n/aQ1 23EPS +14.29%·Rev n/aQ4 22EPS +40.00%·Rev n/aQ3 22EPS +7.69%·Rev n/a⚠ consensus missing

Trevi Therapeutics, Inc. TRVI

Jennifer Good — Chief Executive Officer

Lisa Delfini — Chief Financial Officer

−0.4%1d on move date−0.4% vs SPY3d+1.3%5d−11.7%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TRVI calls or request research access.

More TRVI calls Browse calls Request research access